Nanobiotix is trading 5.3% down now at $42.75 after profit-taking following its recent gains.
- No fresh company-specific announcement, earnings release, or regulatory catalyst was identified for August 28, 2026.
- The decline is also consistent with broader biotechnology weakness: XBI is down 2.31% as investors reduce exposure to growth-focused healthcare stocks amid renewed concerns about Federal Reserve policy and interest rates.
- Goldman Sachs’ ownership stake above 5% was listed separately and not identified as the cause.